Structure Therapeutics Inc. (GPCR)

39,22 -0,11 (-0,28%) Börsenschluss: 04:00PM EDT

Structure Therapeutics Inc.

601 Gateway Boulevard
Suite 900
South San Francisco, CA 94080
United States
(650) 457-1978
https://structuretx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 93

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Raymond C. Stevens Ph.D.	CEO & Director	890,38k	N/A	1964
Mr. Jun S. Yoon	Co- Founder, CFO & Secretary	627,64k	N/A	1978
Dr. Mark A. Bach M.D., Ph.D.	Chief Medical Officer	672,06k	N/A	1957
Dr. Yingli Ma Ph.D.	Chief Technology Officer	497,58k	N/A	1974
Dr. Xichen Lin Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Mr. Tony Peng	Senior Vice President of Legal	N/A	N/A	N/A
Mr. Bob Gatmaitan	Senior Vice President of People	N/A	N/A	N/A
Dr. Hui Lei Ph.D.	Senior Vice President of Chemistry	N/A	N/A	N/A
Dr. Fang Zhang Ph.D.	Executive VP & Head of Biology	N/A	N/A	N/A
Ms. Lani Ibarra	Senior Vice President of Clinical Development Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Corporate Governance

Structure Therapeutics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.